Arylindenopyrimidines and their use as adenosine A2a receptor antagonists

A pharmaceutical salt, subject technology, applied in the field of novel aryl indenopyrimidines, which can solve the problems of sports injury and low sensitivity to neurochemical changes

Inactive Publication Date: 2010-09-15
JANSSEN PHARMA NV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Furthermore, it has been found that A2a knockout mice whose A2a function is genetically blocked are less sensitive to motor impairment and neurochemical changes when they are exposed to the neurotox

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Arylindenopyrimidines and their use as adenosine A2a receptor antagonists
  • Arylindenopyrimidines and their use as adenosine A2a receptor antagonists
  • Arylindenopyrimidines and their use as adenosine A2a receptor antagonists

Examples

Experimental program
Comparison scheme
Effect test

example

example A

example B

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

This invention relates to novel arylindenopyrimidines A, B, and C, and their therapeutic and prophylactic uses. Disorders treated and/or prevented using these compounds include Parkinson's Disease.Formula (I).

Description

Related patent application cross-reference This patent application claims priority to US Provisional Patent Application Serial No. 60 / 982,456, filed October 25, 2007. The entire disclosures of the aforementioned related US patent applications are hereby incorporated by reference herein for all purposes. technical field The present invention relates to novel aryl indenopyrimidines and their therapeutic and prophylactic uses. Disorders that can be treated and / or prevented with these compounds include neurodegenerative disorders and movement disorders that are ameliorated by antagonism of the adenosine A2a receptor. The present patent application relates to a subset of the pending compound species disclosed in patent applications US 20040127510(A1) and WO2005 / 042500A1. Background technique Adenosine A2a Receptor Adenosine is a purine nucleotide produced by all metabolically active cells in the body. Adenosine exerts its effects through four cell surface receptor subtypes ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D239/70C07D403/06C07D401/06A61K31/517A61P25/16
CPCC07D239/70C07D403/06C07D401/06A61P25/00A61P25/14A61P25/16A61P25/22A61P25/24A61P25/28A61P25/30A61P43/00
Inventor B·C·舒克P·F·杰克逊
Owner JANSSEN PHARMA NV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap